Drug intelligence / Profile preview

QLF32004

Development stage: Phase 1
Lead developer: Qilu Pharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Injection

Overview

QLF32004 is an investigational bispecific antibody developed as a class 1 biological drug for the treatment of advanced malignant solid tumors and B-cell malignant tumors. It is administered by injection and is currently being evaluated in early-phase clinical trials to determine its safety, tolerability, pharmacokinetics, and recommended dose for further studies. The precise mechanism of action has not been disclosed. The drug is being developed by Qilu Pharmaceutical and has not yet received regulatory approval in any country[1][2][3].

Targets

TGFB1 (Transforming growth factor Beta-1 proprotein)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on QLF32004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLF32004.

Explore the full profile